Jasper Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Jasper Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($75.80M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($71.27M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($64.47M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($37.69M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($30.64M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($31.67M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($596.4K) | May 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($83.88M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($76.24M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($68.86M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($51.20M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($36.83M) | Mar 8, 2023 |
| FY2023 | Sep 24, 2021 | $2.90M | Mar 5, 2024 |
| FY2021 | Dec 31, 2020 | ($20.68M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($136.3K) | May 24, 2021 |
| FY2023 | Nov 21, 2019 | $2.90M | Mar 5, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.10M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $55.82M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $51.79M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $34.63M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $25.42M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $15.88M | Mar 18, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($77.16M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($62.60M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($52.07M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($45.86M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($33.68M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($18.27M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($367.5K) | May 24, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.78M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $79.90M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $94.89M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $48.36M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $93.65M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $23.36M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $101.69M | May 24, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.63M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $18.23M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $16.45M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $12.37M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $24.14M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $14.65M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $10.85M | May 24, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.15M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $61.67M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $78.44M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $35.99M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $69.52M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | ($35.13M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | ($4.73M) | Mar 18, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($316.67M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($240.87M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($169.60M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($105.14M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($67.45M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($36.81M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($596.4K) | May 24, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.69M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $71.64M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $86.89M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $38.25M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $84.70M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $19.84M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $1.21M | May 24, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (6) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 8, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (6) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 8, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 28.00M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 15.02M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 11.16M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 3.80M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 37.86M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 2.77M | Mar 18, 2022 |